A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy.
Theivanthiran B, Evans KS, DeVito NC, Plebanek M, Sturdivant M, Wachsmuth LP, Salama AK, Kang Y, Hsu D, Balko JM, Johnson DB, Starr M, Nixon AB, Holtzhausen A, Hanks BA.
Theivanthiran B, et al.
J Clin Invest. 2020 May 1;130(5):2570-2586. doi: 10.1172/JCI133055.
J Clin Invest. 2020.
PMID: 32017708
Free PMC article.